Cargando…
A CD21 low phenotype, with no evidence of autoantibodies to complement proteins, is consistent with a poor prognosis in CLL
B-cell chronic lymphocytic leukemia (CLL) is characterized by differential BCR signaling and autoimmune complications. Complement modulates B-cell function via C3d and CD21 cross-linked to the B-cell receptor (BCR). We hypothesized that CD21 contributes to BCR signaling and participates in the autoi...
Autores principales: | Nichols, Eva-Maria, Jones, Rachel, Watson, Rachael, Pepper, Chris J., Fegan, Chris, Marchbank, Kevin J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4741721/ https://www.ncbi.nlm.nih.gov/pubmed/26452134 |
Ejemplares similares
-
Telomere fusions associate with coding sequence and copy number alterations in CLL
por: Escudero, Laura, et al.
Publicado: (2019) -
Telomere length predicts for outcome to FCR chemotherapy in CLL
por: Norris, Kevin, et al.
Publicado: (2019) -
NF-kB and the CLL microenvironment
por: O’Donnell, Alice, et al.
Publicado: (2023) -
The Hsp90 inhibitor NVP-AUY922-AG inhibits NF-κB signaling, overcomes microenvironmental cytoprotection and is highly synergistic with fludarabine in primary CLL cells
por: Walsby, Elisabeth, et al.
Publicado: (2012) -
Phenotypic heterogeneity in IGHV-mutated CLL patients has prognostic impact and identifies a subset with increased sensitivity to BTK and PI3Kδ inhibition
por: Pepper, C, et al.
Publicado: (2015)